Clinical Trial

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Safety and Efficacy Evaluation of Tremelimumab Plus Durvalumab(MEDI4736) in Combination with Concurrent Transarterial Chemoembolization in Unresectable Hepatocellular carcinoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-28.
Status change: Not Yet Recruiting → Recruiting 2025-05-13
Trial Details
NCT Number NCT06911255
Lead Sponsor Yoon Jun Kim
Collaborators: AstraZeneca
Conditions Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Enrollment 24 participants
Start Date 2025-04-18
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-14